Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial
Authors' conclusion
In people with CKD and type 2 diabetes the use of short-acting GLP-1 RA lixisenatide did not significantly influence Ao-PWV. Further studies are needed to understand mechanisms that may explain discordance in CVOTs results observed with GLP-1 RA.
Study context
- Population
- People with T2D and chronic kidney disease (CKD)90 analysed
- Participants
- 101 people
- Comparison
- Lixisenatide vs placebo for 24 weeks
- Lixisenatiden = 47
- Placebon = 43reference
- Primary endpoint
- Ao-PWV
- Follow-up
- 24 weeks
Methodological detailsproof-of-concept, single centre, double-blind, parallel-group, placebo-controlled
- Proof-of-concept
- Single centre
- Double-blind
- Parallel-group
- Placebo-controlled
Primary result
As reported in the abstract
P = 0.38
Further findings
Cardio-renal risk biomarkers incl. albuminuria and Klotho
- No significant changes in cardio-renal risk biomarkers including albuminuria and Klotho levels
HbA1c
- HbA1c decreased with lixisenatide vs placebo
Original publication
Effect of lixisenatide on arterial stiffness in people with type 2 diabetes and kidney disease: Results of a randomised controlled trial. Diabetes Obes Metab. Published 18 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →